Marvin R. Garovoy

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California.

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron.

XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA.

AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018.